|
| Study ID |
Sample size
(EG/CG) |
Age (yrs)
(mean) |
Sex
(male/female) | Diagnostic criteria | Intervention |
Adverse events (cases) |
Outcomes |
| Experimental group | Control group |
|
| Zuo et al. (2015) [29] | 46/47 | EG: 56.22 ± 9.92
CG: 58.58 ± 8.84 | EG: 7/34
CG: 6/32 | ACR | Fufang Xiatianwu pill (0.6 g, tid, 12 w) | Diclofenac sodium (25 mg, tid, 12 w) | EG: GS (10)
CG: GS (18) | VAS-2; SF-36; WOMAC; |
|
| Huang and Quan (2015) [30] | 34/34 | EG: 53–76 (68)
CG: 53–76 (65) | EG: 19/15
CG: 18/16 | ACR | Huo xue zhi tong capsule (2 pills, tid, 4 w) + CG | Sodium hyaluronate
(IA, 2 mL, qw, 4 w) | EG: GS (1)
CG: GS (2) | VAS-1 |
|
| Cao et al. (2015) [31] | EG1/EG2/CG: 30/30/30 | EG1: 61.57 ± 6.68 EG2: 61.03 ± 5.89
CG: 61.41 ± 7.15 | EG1: 8/22
EG2: 9/21
CG: 6/24 | CMA
(2007) | EG1: Jin tian ge capsule (3 pills, tid, 1 m);
EG2: EG1 + CG | Aceclofenac
(0.1 g, bid, 1 m); | EG1: None
EG2: GS (1)
CG: GS (1) | Lequesne |
|
| Zhang et al. (2013) [32] | 63/61 | EG: 38–70 (56.3)
CG: 39–73 (57.6) | EG: 13/50
CG: 12/49 | ACR
(1995) | Pan long qi pill (0.9 g, tid, 4 w) + CG | Diacerein (50 mg, bid, 4 w) + Aceclofenac (0.1 g, bid, 4 w) | EG: GS (1);
CG: ALF (1) | WOMAC |
|
| Yi and Ji (2013) [33] | 30/30 | EG: 40–70 (54.5)
CG: 39–72 (55.3) | EG: 9/21
CG: 8/24 | ACR | Pan long qi pill (3 pills, tid, 6 w) | Glucosamine
(250 mg, tid, 6 w) | EG: GS (1)
CG: GS (1) | VAS-1; VAS-2 |
|
| Niu et al. (2013) [34] | 27/33 | NR | NR | CMA
(2003) | Jin gu tong xiao pill (6 g, bid, 1 m) + CG | Glucosamine
(2 pills, tid, 1 m) | None | Lequesne; SF-36 |
|
| Liao (2013) [35] | 230/230 | EG: 57.67 ± 7.62
CG: 57.43 ± 7.81 | EG: 105/125
CG: 101/129 | NR | Jiangu granule (12 g, tid, 1 m) | Sodium hyaluronate
(IA, 20 mg, qw, 1 m) | EG: DM (3); GS (2)
CG: DM (1); GS (1) | VAS-1 |
|
| Li et al. (2013) [36] | 105/105 | EG: 38–54 (45.0)
CG: 40–52 (46.3) | EG: 70/35
CG: 72/33 | ACR
(1995) | Hua mo yan granule (12 g, tid, 4 w) | Ketoprofen (50 mg, tid, 4 w) | NR | VAS-1 |
|
| Li et al. (2013) [37] | 93/93 | EG: 56.2 ± 6.7
CG: 54.8 ± 7.2 | EG: 40/53
CG: 38/55 | CMA
(2007) | Hua mo yan granule (12 g, tid, 4 w) + CG | Infrared therapy
(15 min, bid) | None | VAS-1 |
|
| Li et al. (2013) [38] | EG1/EG2/CG1/CG2: 50/50/50/50 | EG1: 64.23 ± 1.69
EG2: 64.56 ± 1.75
CG1: 64.35 ± 1.78
CG2: 63.85 ± 1.72 | EG1: 22/28
EG2: 23/27
CG1: 23/27
CG2: 24/26 | ACR | EG1: Fu gui gu tong granule (5 g, tid, 1 m)
EG2: EG1 + CG2 | CG1: Diclofenac sodium (25 mg, tid, 1 m)
CG2: Ozone (IA, 10 mL, qw, 1 m) | GS | VAS-1; WOMAC |
|
| Chen et al. (2013) [39] | EG1/EG2/CG: 48/48/48 | EG1: 58 ± 17.7
EG2: 61 ± 18.6
CG: 61 ± 16.0 | EG1: 17/25
EG2: 15/25
CG: 14/28 | CMA
(2003) | EG1: Xian ling gu bao capsule (1.5 g, bid, 4 w)
EG2: EG1 + CG | Ozone (IA, 15 mL, qw, 4 w) | EG1: None
EG2: LS (7)
CG: LS (7) | VAS-1; Lysholm |
|
| Luo et al. (2012) [40] | EG1/EG2/CG: 33/34/36 | EG1: 41–74 (51.93)
EG2: 42–67 (50.15)
CG: 39–65 (50.35) | EG1: 15/18
EG2: 17/17
CG: 17/19 | ACR
(1995) | EG1: Xian ling gu bao capsule (1.5 g, bid)
EG2: EG1 + CG | Sodium hyaluronate
(IA, qw, 5 w) | EG1: GS (1)
EG2: GS (1)
CG: None | VAS-1; VAS-2; WOMAC |
|
| Lu et al. (2012) [41] | 120/120 | EG: 52.93 ± 14.22
CG: 54.01 ± 15.35 | EG: 55/65
CG: 50/70 | CMA
(2007) | Teng huang jian gu pill (1.5–3.0 g, bid, 4 w) | Celecoxib (200 mg, qd, 4 w) | EG: None
CG: GS (5) | WOMAC |
|
| Li et al. (2012) [42] | 58/31 | EG: 59.4 ± 10.3
CG: 63.2 ± 14.8 | EG: 22/36
CG: 11/20 | ACR
(1995) | Fufang xiao huo luo pill (2 pills, bid, 2 m) | Glucosamine
(250 mg, bid, 2 m) | None | VAS-1; VAS-2; Lysholm |
|
| Li et al. (2012) [43] | 75/77 | EG: 46–73 (55.2)
CG: 43–72 (54.1) | EG: 22/53
CG: 23/54 | CMA
(2007) | Hua mo yan granule (12 g, tid, 4 w) + CG | Infrared therapy
(15 min, bid, 4 w) | NR | VAS-1 |
|
| Jiang et al. (2012) [44] | 55/55 | EG: 61.92 ± 9.89
CG: 62.78 ± 10.25 | EG: 33/22
CG: 31/24 | ACR
(1986) | Bai shao zong gan capsule (0.3 g, tid, 4 w) + CG | Celecoxib (200 mg, qd, 4 w) | EG: GS (4); ERU (1)
CG: GS (2); ERU (1) | VAS-1 |
|
| Wang et al. (2011) [45] | 49/49 | 56.9 ± 13.0 | 48/50 | ACR
(1995) | Jin tian ge capsule (3 pills, tid, 3 m) + CG | Alfacalcidol (0.5 μg, qd) + Naproxen (0.25, bid) | None | Lequesne |
|
| Kang et al. (2011) [46] | EG1/EG2/CG: 72/46/42 | EG1: 54.34 ± 6.93
EG2: 52.63 ± 7.29
CG: 54.24 ± 6.80 | EG1: 14/58
EG2: 10/32
CG: 12/34 | ACR
(1995) | EG1: Wang bi pill (2.0 g, tid, 8 w)
EG2: EG1 + CG | Diclofenac sodium (25 mg, qd/bid, 8 w) | EG1: GS (2)
EG2: GS (4)
CG: GS (6) | VAS-1 |
|
| Yan (2010) [47] | 30/30 | EG: 57.90 ± 7.10
CG: 59.87 ± 7.24 | EG: 6/23
CG: 6/24 | CMA
(2007) | Kang gu zeng sheng capsule (5 pills, tid, 4 w) | Glucosamine
(2 pills, tid, 4 w) | EG: None
CG: GS (1) | WOMAC |
|
| Xiao et al. (2009) [48] | 77/77 | EG: 56.20 ± 10.64
CG: 57.49 ± 12.82 | EG: 21/53
CG: 18/52 | NR | Pan long qi pill (3 pills, tid, 6 w) | Diclofenac sodium (25 mg, tid, 6 w) | EG: GS (3); DIZ (2)
CG: GS (3) | VAS-2 |
|
| Qi and Xu (2009) [49] | 60/60 | EG: 45–69
CG: 46–70 | EG: 13/47
CG: 11/49 | GCRNDTCM | Xin huang pill (1.28 g, tid, 15 d) | Ibuprofen (0.6 g, bid, 15 d) +
Indometacin (25 mg, tid, 15 d) | EG: GS (2)
CG: GS (12) | Lysholm |
|
| Li (2009) [50] | 50/50 | EG: 45–68 (51.8)
CG: 46–67 (52.6) | EG: 22/28
CG: 23/27 | ACR | Bi qi capsule (1.2 g, tid, 6 w) | Glucosamine
(250 mg, tid, 6 w) | NR | HSS |
|
| H. B. Liu and J. Liu (2007) [51] | 66/64 | EG: 59.5 ± 9.4
CG: 58 ± 8.5 | EG: 23/43
CG: 26/38 | ACR | Jin gu tong xiao pill (6 g, bid, 2 m) + CG | Sodium hyaluronate (IA, 5 mL, q4w, 4 w) | None | Lysholm |
|
| Chen et al. (2007) [52] | 37/34 | 47–76 | 24/47 | ACR
(1986) | Gu jin pill (0.9 g, tid, 8 w) | Diclofenac sodium (75 mg, qd, 8 w) | None | Lysholm |
|
| Yang et al. (2006) [53] | 60/60 | EG: 45–68 (51.2)
CG: 46–65 (53.1) | EG: 28/32
CG: 26/34 | ACR | Pan long qi pill (3 pills, tid, 6 w) | Glucosamine
(250 mg, tid, 6 w) | NR | VAS-1; VAS-2 |
|
| Xu et al. (2004) [54] | 30/30 | 50–79 | 25/35 | ACR | Bai shao zong gan capsule (0.6 g, bid, 6 w) | Nabumetone (1.0 g, qd, 6 w) | EG: None
CG: GS (8) | VAS-1 |
|
